Literature DB >> 9041748

The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer.

N Muñoz1, F X Bosch.   

Abstract

This article reviews epidemiologic evidence linking human papillomavirus (HPV) to cervical cancer. The authors conclude that over 90% of all cervical cancers can be attributed to certain HPV types-HPV 16 accounting for the largest proportion (roughly 50%) followed by HPV 18 (12%), HPV 45 (8%), and HPV 31 (5%). Recognition of this circumstance has far-reaching implications for primary and secondary prevention of this malignancy. At present, prophylactic and therapeutic HPV vaccines are under development, and HPV typing is being integrated into pilot study screening programs in a few developed countries. In developing countries, well conducted conventional screening programs remain the best approach for the control of cervical cancer until a safe and efficient HPV vaccine can be developed for use by the general population.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9041748

Source DB:  PubMed          Journal:  Bull Pan Am Health Organ        ISSN: 0085-4638


  14 in total

Review 1.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

2.  Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies.

Authors:  R C Rose; W I White; M Li; J A Suzich; C Lane; R L Garcea
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

3.  Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results.

Authors:  Matthew P Stevens; Suzanne M Garland; Elice Rudland; Jeffrey Tan; Michael A Quinn; Sepehr N Tabrizi
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

4.  Correlation of human papilloma virus with oral squamous cell carcinoma in Chinese population.

Authors:  Jingping Zhou; Detao Tao; Daofang Tang; Zhenlin Gao
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 5.  HPV as a model for the development of prophylactic and therapeutic cancer vaccines.

Authors:  Raed N Samara; Samir N Khleif
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

6.  Comparison of the DiagCor GenoFlow Human Papillomavirus Array Test and Roche Linear Array HPV Genotyping Test.

Authors:  Fiona K Y Wong; Johannes C Y Ching; Joseph K F Chow
Journal:  Open Virol J       Date:  2010-11-03

7.  Prevalence of DNA-HPV in male sexual partners of HPV-infected women and concordance of viral types in infected couples.

Authors:  Maria Gabrielle de Lima Rocha; Fabio Lopes Faria; Leonor Gonçalves; Maria do Carmo M Souza; Paula Ávila Fernandes; Ana Paula Fernandes
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

8.  Cost-effectiveness of a potential vaccine for human papillomavirus.

Authors:  Gillian D Sanders; Al V Taira
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

9.  The relationship between oral squamous cell carcinoma and human papillomavirus: a meta-analysis of a Chinese population (1994-2011).

Authors:  Changtai Zhu; Yang Ling; Chunlei Dong; Xifa Zhou; Feng Wang
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

10.  Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology.

Authors:  S R Wall; C F Scherf; L Morison; K W Hart; B West; G Ekpo; A N Fiander; S Man; C M Gelder; G Walraven; L K Borysiewicz
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.